Exploring membranous NECTIN‐4 expression patterns and enfortumab vedotin response in prostate cancer
Exploring membranous NECTIN‐4 expression patterns and enfortumab vedotin response in prostate cancer
About this item
Full title
Author / Creator
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Antibody‐drug conjugates (ADCs) represent a novel type of targeted cancer therapy combining the specificity of monoclonal antibodies with the cytotoxicity of conventional chemotherapy. Recently, ADCs have demonstrated practice‐changing efficacy across diverse solid cancers. The anti‐NECTIN‐4 ADC enfortumab vedotin (EV) has just been approved for pa...
Alternative Titles
Full title
Exploring membranous NECTIN‐4 expression patterns and enfortumab vedotin response in prostate cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11284121
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11284121
Other Identifiers
ISSN
1582-1838,1582-4934
E-ISSN
1582-4934
DOI
10.1111/jcmm.18572
